Skip To Main Content
Giovanni Barillari on Muck Rack

Giovanni Barillari

As seen in: Nature, MDPI
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Giovanni

Contact Giovanni, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Multi-omics analyses identify EZH2 as a central driver in rhabdomyosarcoma radioresistance and highlight Tazemetostat as an effective radiosensitizer in vitro and in vivo

|
By Matteo Cassandri, Antonella Porrazzo, Simona Camero, Silvia Pomella, Francesca Vulcano, Francesca Pedini, Andrea Casagrande, Giada Mele, Enrico Romano, Michele Signore, Massimo Spada, Silvia Codenotti, Alessandro Fanzani, Annunziata Mauro, Giovanna Marchese, Simone Sidoli, Giovanni Luca Gravina, Giovanni Barillari, Franco Locatelli, Francesca Megiorni, Rossella Rota, Francesco Marampon, Valeria Manzi, Luisa Milazzo, Deborah Pajalunga, Valentina Lulli, Maria Teresa D’Urso
| Nature Verified
Abstract Rhabdomyosarcoma (RMS), a pediatric soft tissue sarcoma, comprises two major subtypes: fusion-positive (FP), driven by PAX3/7-FOXO1 fusions, and fusion-negative (FN), often harboring RAS pathway mutations. High-risk RMS exhibits intrinsic resistance to radiotherapy (RT), posing a significant clinical hurdle. Emerging evidence implicates EZH2, the catalytic subunit of the Polycomb Repressive Complex 2 (PRC2), in promoting RT resistance through gene silencing via H3K27me3.
Open in Who Shared Issue with article?
See all 1 articles